Literature DB >> 25082283

Anticancer drugs: horizons broaden for PI3Kδ inhibitors.

Katie Kingwell.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25082283     DOI： 10.1038/nrd4399

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.

Authors:  Dalya R Soond; Roberto Pineiro; Khaled Ali; Thorsten Hagemann; Wayne Pearce; Ee Lyn Lim; Hicham Bouabe; Cheryl L Scudamore; Timothy Hancox; Heather Maecker; Lori Friedman; Martin Turner; Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Nature       Date:  2014-06-11       Impact factor: 49.962
  1 in total
  1 in total

Review 1.  A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy.

Authors:  Qiong Xiang; Shuai Dong; Xian-Hui Li
Journal:  Med Sci Monit       Date:  2021-10-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.